GlassScriptPhysician profile
Gina Marie Settle
NPI 1730335506
$5,916.76
in general payments reported to CMS, 2019-2025
26 companies · $1,430 in 2025
The $1,430 reported for 2025 was more than what 87% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $191 · 2022: $1,450 · 2023: $1,815 · 2024: $1,030 · 2025: $1,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,263 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,263.09 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $699.39 | 2022-2025 | Caplyta |
| Corium, LLC | $448.56 | 2021-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $419.09 | 2021-2024 | Spravato |
| Axsome Therapeutics, INC. | $380.99 | 2023-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $358.44 | 2021-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $350.83 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $315.80 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $315.60 | 2022-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $308.61 | 2022-2025 | Austedo Xr, Austedo, Austedo Xr |
| Noven Therapeutics, LLC | $305.11 | 2023-2025 | Xelstrym |
| Lundbeck LLC | $297.18 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $294.55 | 2022-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $263.85 | 2021-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $237.57 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $199.84 | 2021-2025 | Ingrezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $138.41 | 2022-2025 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $133.90 | 2022-2024 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $105.57 | 2022 | |
| Collegium Pharmaceutical, INC. | $92.01 | 2025 | Jornay Pm |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $61.23 | 2025 | |
| Almatica Pharma LLC | $45.36 | 2025 | Loreev Xr |
| E.R. Squibb & Sons, L.L.C. | $45.19 | 2024 | Cobenfy |
| Neos Therapeutics, LP | $41.98 | 2023-2025 | Adzenys Xr-Odt |
| Jazz Pharmaceuticals INC. | $22.86 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.71 | 2025 | Relexxii |
| Azurity Pharmaceuticals, INC. | $17.13 | 2025 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Settle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.